Last updated: February 20, 2026
What is the Product Profile and Market Position?
Iopamidol-200 is a non-ionic contrast agent primarily used in radiology for diagnostic imaging procedures such as computed tomography (CT). It contains 200 mg/mL of the active pharmaceutical ingredient (API), Iopamidol, packaged in pre-filled plastic containers.
The spatial market comprises hospitals, diagnostic laboratories, and imaging centers, predominantly in North America, Europe, and Asia-Pacific. The global contrast media market was valued at approximately USD 3.81 billion in 2021 and is projected to reach USD 5.2 billion by 2028, growing at a CAGR of 4.4% [1].
What are the key demand drivers?
- Increased utilization of CT imaging globally
- Growing prevalence of cardiovascular diseases and cancer
- Rising investments in healthcare infrastructure
- Adoption of minimally invasive diagnostic procedures
Contrast agents like Iopamidol-200 in plastic containers are the preferred choice due to convenience, safety, and sterilization effectiveness.
What are the competitive and regulatory considerations?
- Low entry barriers due to existing regulatory frameworks in major markets
- Dominant players include Bracco, GE Healthcare, and Bayer
- Entry requires FDA, EMA, and other regional approvals, which involves a review period of 6–12 months and compliance with standards such as USP, Ph. Eur.
- Patent landscape is mature; Iopamidol patents have expired, opening opportunities for generics
What are the production and supply chain fundamentals?
- Manufacturing requires specialized facilities adhering to Good Manufacturing Practice (GMP)
- API synthesis involves complex multi-step processes with high purity requirements
- Packaging in plastic containers necessitates compatibility testing with the API and excipients
- Supply chain depends on reliable sourcing of raw materials, cold chain logistics, and regulatory compliance for international distribution
What are the investment considerations?
| Factor |
Observation |
| Market Growth |
Growing demand supports revenue expansion |
| Competitive Landscape |
Patent expirations allow new entrants; brand loyalty favors incumbents |
| Regulatory Barriers |
Moderate; established approval pathways for generics present lower risk |
| Margin Profile |
High for branded products; generics may see reduced margins due to competition |
| Cost of Entry |
Considerable, due to GMP compliance, regulatory fees, and clinical testing |
Financial and Strategic Outlook
Investors should consider the timeline from registration to market launch, which spans 6–18 months. Initial investment includes regulatory fees, manufacturing setup, and clinical validation. The market median price for contrast agents in plastic containers is approximately USD 10–20 per injection. Volume sales depend on hospital procurement cycles and imaging center agreements.
Potential for revenue growth exists if the product gains rapid approval and secures sizeable distribution channels. Price competition, however, can erode margins, especially among generics.
Risks and Challenges
- Regulatory delays in new markets can extend time-to-market
- Price erosion due to generic competition upon patent expiration
- Supply chain disruptions affecting raw material availability
- Market penetration risk due to existing dominant players
Key Takeaways
- Iopamidol-200 in plastic containers addresses a stable, growing global demand for imaging contrast media.
- Market expansion hinges on regulatory approval, manufacturing compliance, and distribution network effectiveness.
- Competitive advantage depends on product differentiation, pricing strategies, and regulatory speed.
- Investment risks involve market saturation, regulatory hurdles, and margin decline with potential generic entry.
- Infrastructure costs remain high but are offset by a sizable existing demand pipeline.
FAQs
1. How long does regulatory approval take for contrast agents?
Typically, 6–12 months in major markets, depending on submission completeness and regulatory review load [2].
2. What are the primary cost drivers?
API procurement, GMP-compliant manufacturing, regulatory submission fees, and quality assurance processes.
3. What is the typical price per unit for contrast agents?
USD 10–20 per injection, variable by region and volume sales agreements.
4. Who are the main competitors?
Bracco (Italia), GE Healthcare (USA), Bayer (Germany), with a dominant market share in contrast agents.
5. What are the primary risks of entering this market?
Regulatory delays, high entry costs, pricing pressures from generics, and supply chain bottlenecks.
References
[1] Research and Markets. (2022). Contrast Media Market Forecast. https://www.researchandmarkets.com/reports/contrast-media-market
[2] U.S. Food and Drug Administration. (2022). Drug Approval Process. https://www.fda.gov/drugs/drug-approvals-and-databases/steps-process
End of report
